Journal
ARCHIVES OF OPHTHALMOLOGY
Volume 125, Issue 6, Pages 783-788Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archopht.125.6.783
Keywords
-
Categories
Funding
- NEI NIH HHS [R01 EY012963-07, R01 EY012963, EY014786, EY12963, F32 EY014786] Funding Source: Medline
Ask authors/readers for more resources
Objective: To investigate the role of very late antigen 1 ( VLA-1) ( also known as integrin receptor alpha(1)beta(1)) in corneal transplantation inflammation and allograft survival. Methods: Cell infiltration and vasculogenesis ( both angiogenesis and lymphangiogenesis) associated with allodisparate corneal transplantation were assessed in VLA-1-deficient conditions and controls by immunofluorescent microscopic studies. Corneal allograft survival was also assessed after anti-VLA-1 antibody treatment and in VLA-1 knockout recipient mice. Results: Anti-VLA-1 antibody treatment leads to a profound reduction in the granulocytic, monocytic, and T-cell infiltration after corneal transplantation. In addition, corneal angiogenesis and lymphangiogenesis were both significantly suppressed in VLA-1 knockout mice. Remarkably, universal graft survival was observed in both anti VLA-1 antibody treatment and knockout mice. Conclusions: Very late antigen 1 blockade markedly reduces inflammation and inflammation-induced tissue responses, including vasculogenic responses, associated with corneal transplantation and promotes allograft survival. Clinical Relevance: These studies offer insights into important integrin-mediated mechanisms of corneal transplant - related inflammation and provide possible new integrin-based immunotherapies for transplant rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available